Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course
R.B. Warren
Dermatological Sciences, The University of Manchester, Manchester Academic Health Sciences Centre, Salford Royal Foundation Trust, Manchester, UK
Search for more papers by this authorC.E. Kleyn
Dermatological Sciences, The University of Manchester, Manchester Academic Health Sciences Centre, Salford Royal Foundation Trust, Manchester, UK
Search for more papers by this authorW.P. Gulliver
Division of Dermatology, Memorial University of Newfoundland, St John’s, Newfoundland, Canada
Search for more papers by this authorR.B. Warren
Dermatological Sciences, The University of Manchester, Manchester Academic Health Sciences Centre, Salford Royal Foundation Trust, Manchester, UK
Search for more papers by this authorC.E. Kleyn
Dermatological Sciences, The University of Manchester, Manchester Academic Health Sciences Centre, Salford Royal Foundation Trust, Manchester, UK
Search for more papers by this authorW.P. Gulliver
Division of Dermatology, Memorial University of Newfoundland, St John’s, Newfoundland, Canada
Search for more papers by this authorFunding sources Financial support for writing assistance and publication of this supplement was supplied by Abbott Laboratories.
Conflicts of interest R.B.W. has acted as a consultant and/or speaker for Abbott, Janssen Cilag, Leo Pharma, Merck-Serono, Pfizer, Schering Plough and Wyeth. C.E.K. has acted as a consultant and/or speaker for Abbott, GlaxoSmithKline, Janssen Cilag, Leo Pharma, Schering Plough and Wyeth and received research funding (unrestricted educational grants) from Merck-Serono and Janssen Cilag. W.P.G. has acted as an investigator, speaker and advisor and has received research funding from Abbott, and has acted as an investigator, speaker and advisor for Merck.
Summary
Psoriasis is associated with significant physical, psychological, social and economic burden, the cumulative effect of which may result in failure to achieve ‘full life potential’ in some patients, termed ‘cumulative life course impairment’ (CLCI). In this concept, the burden of stigmatization, and physical and psychological comorbidities (risk factors for cumulative impairment) and coping strategies and external factors (having potential moderating effects), interact to cause lifetime impairment. Components of CLCI are supported by cross-sectional data; however, the cumulative nature of impairment in patients with psoriasis is not yet established. Nonetheless, CLCI makes intuitive sense to many dermatologists who recognize the cumulative impact of psoriasis on the lives of some patients. This supplement explores the causes and mechanisms of CLCI qualitatively by presenting cases which are representative of typical patients with moderate-to-severe psoriasis. These cases demonstrate the effect of psoriasis in influencing major life-changing decisions and altering the course of patients’ lives, preventing patients from attaining their life goals, pursuing their chosen career, gaining a desired educational level, developing social relationships, gaining full pleasure from family life or having children. All these patients believe that their lives would have taken a different course had they not had psoriasis. Additional research to determine how CLCI occurs and to identify the risk factors for cumulative impairment is required. Understanding the key risk factors for CLCI may help physicians identify patients who are more vulnerable to the cumulative impact of psoriasis, resulting in more appropriate treatment decisions earlier in the disease course.
References
- 1 Kimball AB, Gieler U, Linder D, et al. Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol 2010; 24: 989–1004.
- 2
D Kuh,
Y Ben-Shlomo, eds. A Life Course Approach to Chronic Disease Epidemiology, 2nd edn. Oxford: Oxford University Press, 2004.
10.1093/acprof:oso/9780198578154.001.0001 Google Scholar
- 3 GH Elder, JZ Giele eds. The Craft of Life Course Research. New York: The Guilford Press, 2009.
- 4 Bhatti ZU, Finlay AY, Salek S. Chronic skin diseases influence major life-changing decisions: a new frontier in health outcomes research. Br J Dermatol 2009; 161: 58–9.
- 5 Bhatti ZU, Salek S, Finlay AY. The influence of chronic skin diseases on major life-changing decisions as a parameter for the assessment of long-term impact. Br J Dermatol 2010; 163: 39–40.
- 6 Bhatti Z, Salek M, Finlay A. Major life changing decisions and cumulative life course impairment. J Eur Acad Dermatol Venereol 2011; 25: 245–6.
- 7 Kimball A, Gieler U, Linder D, et al. Re: major life-changing decisions and cumulative life course impairment. J Eur Acad Dermatol Venereol 2011; 25: 246.
- 8 Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR, et al. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003; 48: 882–5.
- 9 Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2010; doi: 10.1111/j.1365-2796.2010.02310.x. Oct 29 (Epub ahead of print).
- 10 Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586–92.
- 11 Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000–6.
- 12 Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145: 700–3.
- 13 Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493–9.
- 14 Gulliver WP, Macdonald D, Gladney N, et al. Long-term prognosis and comorbidities associated with psoriasis in the Newfoundland and Labrador founder population. J Cutan Med Surg 2011; 15: 37–47.
- 15 Jobling R. Psoriasis. BMJ 2007; 334: 953–4.
- 16 International Federation of Psoriasis Associations (IFPA). Under the spotlight: revealing the real life impact of psoriasis over time. 2010. Available at: http://www.underthespotlight.com/index.html (last accessed 2 March 2011).
- 17 Ginsburg IH, Link BG. Psychosocial consequences of rejection and stigma feelings in psoriasis patients. Int J Dermatol 1993; 32: 587–91.
- 18 Vardy D, Besser A, Amir M, et al. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 2002; 147: 736–42.
- 19 Richards HL, Fortune DG, Griffiths CE, et al. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 2001; 50: 11–15.
- 20 Richards HL, Fortune DG, Main CJ, et al. Stigmatization and psoriasis. Br J Dermatol 2003; 149: 209–11.
- 21 CPGC. Canadian guidelines for the management of plaque psoriasis. 2009. Available at: http://www.dermatology.ca/psoriasisguidelines (last accessed 2 March 2011).
- 22 Weiss SC, Kimball AB, Liewehr DJ, et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47: 512–18.
- 23 Fortune DG, Main CJ, O’Sullivan TM, et al. Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory. J Psychosom Res 1997; 42: 467–75.
- 24 Fortune DG, Richards HL, Corrin A, et al. Attentional bias for psoriasis-specific and psychosocial threat in patients with psoriasis. J Behav Med 2003; 26: 211–24.
- 25 Fox FE, Rumsey N, Morris M. ‘Ur skin is the thing that everyone sees and you cant change it!’: exploring the appearance-related concerns of young people with psoriasis. Dev Neurorehabil 2007; 10: 133–41.
- 26 Kuh D, Ben-Shlomo Y, Lynch J, et al. Life course epidemiology. J Epidemiol Community Health 2003; 57: 778–83.
- 27 Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031–42.
- 28 Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn’s disease. J Am Acad Dermatol 2003; 48: 805–21. quiz 22-4.
- 29 Reich K, Kruger K, Mossner R, et al.. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009; 160: 1040–7.
- 30 Boehncke WH, Boehncke S. Managing comorbidities in psoriasis. Actas Dermosifiliogr 2009; 100 (Suppl. 2): 22–7.
- 31 Cohen AD, Dreiher J, Shapiro Y, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008; 22: 585–9.
- 32 Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152–5.
- 33 Qureshi AA, Choi HK, Setty AR, et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009; 145: 379–82.
- 34 Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321–8.
- 35 Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829–35.
- 36 Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case–control study. Br J Dermatol 2007; 157: 68–73.
- 37 Gisondi P, Targher G, Zoppini G, et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758–64.
- 38 Gisondi P, Farina S, Giordano MV, et al. Usefulness of the Framingham risk score in patients with chronic psoriasis. Am J Cardiol 2010; 106: 1754–7.
- 39 Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl. 2): ii14–17.
- 40 Husted JA, Gladman DD, Farewell VT, et al. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997; 24: 511–17.
- 41 Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002; 82: 108–13.
- 42 Husted JA, Tom BD, Farewell VT, et al. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time? Arthritis Rheum 2007; 56: 840–9.
- 43 McKenna SP, Doward LC, Whalley D, et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004; 63: 162–9.
- 44 Wallenius M, Skomsvoll JF, Koldingsnes W, et al. Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis 2009; 68: 685–9.
- 45 Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997; 40: 1868–72.
- 46 Gladman DD, Farewell VT, Wong K, et al. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998; 41: 1103–10.
- 47 Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383–92.
- 48 Lynde CW, Poulin Y, Guenther L, et al. The burden of psoriasis in Canada: insights from the pSoriasis Knowledge IN Canada (SKIN) survey. J Cutan Med Surg 2009; 13: 235–52.
- 49
Waters HC,
Carter CT,
Piech CT.
The impact of psoriasis on psychological functioning and quality of life.
J Am Acad Dermatol
2009; 60: AB183.
10.1016/j.jaad.2008.11.793 Google Scholar
- 50 Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology 2007; 215: 17–27.
- 51 Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891–5.
- 52 Eghlileb AM, Davies EE, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol 2007; 156: 1245–50.
- 53 Evers AW, Verhoeven EW, Kraaimaat FW, et al. How stress gets under the skin: cortisol and stress reactivity in psoriasis. Br J Dermatol 2010; 163: 986–91.
- 54 Reich A, Wojcik-Maciejewicz A, Slominski AT. Stress and the skin. G Ital Dermatol Venereol 2010; 145: 213–19.
- 55 Jankovic S, Raznatovic M, Marinkovic J, et al. Relevance of psychosomatic factors in psoriasis: a case–control study. Acta Derm Venereol 2009; 89: 364–8.
- 56 Verhoeven EW, Kraaimaat FW, de Jong EM, et al. Individual differences in the effect of daily stressors on psoriasis: a prospective study. Br J Dermatol 2009; 161: 295–9.
- 57 Finzi A, Colombo D, Caputo A, et al. Psychological distress and coping strategies in patients with psoriasis: the PSYCHAE study. J Eur Acad Dermatol Venereol 2007; 21: 1161–9.
- 58 Frangos JE, Kimball AB. Divorce/marriage ratio in patients with psoriasis compared to patients with other chronic medical conditions. J Invest Dermatol 2008; 128: S87.
- 59 Magin P, Heading G, Adams J, et al. Sex and the skin: a qualitative study of patients with acne, psoriasis and atopic eczema. Psychol Health Med 2010; 15: 454–62.
- 60 Sampogna F, Gisondi P, Tabolli S, et al. Impairment of sexual life in patients with psoriasis. Dermatology 2007; 214: 144–50.
- 61 Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999; 135: 1490–3.
- 62 Scharloo M, Kaptein AA, Weinman J, et al. Patients’ illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up. Br J Dermatol 2000; 142: 899–907.
- 63 Hill L, Kennedy P. The role of coping strategies in mediating subjective disability in people who have psoriasis. Psychol Health Med 2002; 7: 261–9.
- 64 Fortune DG, Richards HL, Kirby B, et al. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 2002; 146: 458–65.
- 65 Fortune DG, Richards HL, Griffiths CE, et al. Targeting cognitive-behaviour therapy to patients’ implicit model of psoriasis: results from a patient preference controlled trial. Br J Clin Psychol 2004; 43: 65–82.
- 66 Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280–4.
- 67 Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236–44.
- 68 Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006; 213: 102–10.
- 69 Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007; 57: 963–71.
- 70 Sohn S, Schoeffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006; 212: 137–44.
- 71 Ben-David G, Sheiner E, Hallak M, et al. Pregnancy outcome in women with psoriasis. J Reprod Med 2008; 53: 183–7.
- 72 Cohen-Barak E, Nachum Z, Rozenman D, et al. Pregnancy outcomes in women with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2010; doi: 10.1111/j.1463.2010.03917.x. Nov 25 (Epub ahead of print).
- 73 Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008; 59: 295–315.
- 74 Griffiths CE. Management of psoriasis in pregnancy: time to deliver? Br J Dermatol 2010; 163: 235.
- 75 Weatherhead S, Robson SC, Reynolds NJ. Management of psoriasis in pregnancy. BMJ 2007; 334: 1218–20.
- 76 Yang YW, Chen CS, Chen YH, Lin HC. Psoriasis and pregnancy outcomes: a nationwide population-based study. J Am Acad Dermatol 2011; 64: 71–7.
- 77 Unaeze J, Nijsten T, Murphy A, et al. Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol 2006; 126: 1480–9.
- 78 Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med 1999; 48: 1507–15.
- 79 Manuel GM, Roth S, Keefe FJ, et al. Coping with cancer. J Human Stress 1987; 13: 149–58.
- 80 Cioffi D. Beyond attentional strategies: cognitive-perceptual model of somatic interpretation. Psychol Bull 1991; 109: 25–41.
- 81 Warren S, Warren KG, Cockerill R. Emotional stress and coping in multiple sclerosis (MS) exacerbations. J Psychosom Res 1991; 35: 37–47.
- 82 Fortune D, Roberts R, Towell T. Depression in multiple sclerosis: the contribution of psychosocial mediators. Presented at the 10th European Health Psychology Conference, Dublin, Ireland, 1996.
- 83 Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008; 159 (Suppl. 2): 2–9.
- 84 Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485–96.
- 85 Schmid-Ott G, Kunsebeck HW, Jager B, et al. Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derm Venereol 2005; 85: 27–32.
- 86 Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 2003; 4: 833–42.
- 87 Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64 (Suppl. 2): ii18–23. discussion ii4-5.
- 88
R Lerner,
L Steinberg, eds. Handbook of Adolescent Psychology, 2nd edn. New York: Wiley, 2004.
10.1002/9780471726746 Google Scholar
- 89 Coleman J, Hendry L. The Nature of Adolescence, 2nd edn. Florence, KY: Taylor & Francis/Routledge, 1990.
- 90 Alexandroff AB, Pauriah M, Camp RD, et al. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009; 161: 1–7.
- 91 Dantzer R, O’Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46–56.
- 92 Glassman AH, Miller GE. Where there is depression, there is inflammation... sometimes! Biol Psychiatry 2007; 62: 280–1.
- 93 Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29–35.
- 94 Baran R. The burden of nail psoriasis: an introduction. Dermatology 2010; 221 (Suppl. 1): 1–5.
- 95 de Bes J, Legierse CM, Prinsen CA, et al. Patient education in chronic skin diseases: a systematic review. Acta Derm Venereol 2011; 91: 12–17.
- 96 McCrae R, Costa PT. Personality, coping, and coping effectiveness in an adult sample. J Pers 2006; 54: 385–404.
- 97 Augustin M, Kruger K, Radtke MA, et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366–72.
- 98 Nast A, Reytan N, Rosumeck S, et al. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol 2008; 22: 1337–42.
- 99 Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007; 57: 957–62.
- 100 Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1–10.
- 101 Renzi C, Di Pietro C, Gisondi P, et al. Insufficient knowledge among psoriasis patients can represent a barrier to participation in decision-making. Acta Derm Venereol 2006; 86: 528–34.
- 102 Courtenay M, Carey N, Stenner K, et al. Patients views of nurse prescribing: effects on care, concordance and medicine taking. Br J Dermatol 2011; 164: 396–401.
- 103 Bjarkoy RO, Gjengedal E, Wahl AK. Care in the context of the complexity of psoriasis. Clin Nurs Res 2011; 20: 47–63.